MARKET

MCRB

MCRB

Seres
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.02
-1.09
-6.02%
Opening 11:03 03/05 EST
OPEN
19.23
PREV CLOSE
18.11
HIGH
19.23
LOW
16.58
VOLUME
733.85K
TURNOVER
--
52 WEEK HIGH
38.50
52 WEEK LOW
2.520
MARKET CAP
1.56B
P/E (TTM)
-15.1222
1D
5D
1M
3M
1Y
5Y
DJ Seres Therapeutics Price Target Raised to $30.00/Share From $27.50 by Chardan Capital
Dow Jones · 2h ago
DJ Seres Therapeutics Raised to Buy From Neutral by Chardan Capital
Dow Jones · 2h ago
Analyst Actions: Chardan Upgrades Seres Therapeutics to Buy From Neutral, Adjusts Price Target to $30 From $27.50
MT Newswires · 6h ago
Human Microbiome Therapeutics Market 2027 | Major Factors by Industry Size, Share, Business Development Plans, Market Dynamics and Forecast to reach 1,544.6 Million USD | Market Study Report LLC
Mar 04, 2021 (Market Insight Reports) -- Selbyville, Delaware. The business intelligence report on Human Microbiome Therapeutics market offers a detailed...
Market Insight Reports · 1d ago
Global Human Microbiome Market 2020 Report - Trends in Technological Strategies, Business Advancements and Top-Vendor Landscape to 2025
Mar 03, 2021 (CDN Newswire via Comtex) -- Global Human Microbiome Market 2020 by Company, Regions, Type and Application, Forecast to 2026 aims to deliver...
CDN Newswire · 1d ago
Global Human Micobiome Market Size Study with COVID-19 Impact 2020 Research Strategies and Forecast to 2025
Mar 03, 2021 (CDN Newswire via Comtex) -- The recently uploaded report titled Global Human Micobiome Market 2020 by Company, Regions, Type and Application,...
CDN Newswire · 1d ago
Oppenheimer Assigns a Buy Rating on Seres Therapeutics (MCRB)
In a report released yesterday, Mark Breidenbach from Oppenheimer assigned a Buy rating to Seres Therapeutics (MCRB), with a price target of $38.00. The
SmarterAnalyst · 2d ago
Seres Therapeutics (MCRB) Reports Q4 Loss, Tops Revenue Estimates
Zacks.com · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MCRB. Analyze the recent business situations of Seres through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MCRB stock price target is 37.50 with a high estimate of 49.00 and a low estimate of 24.00.
EPS
Institutional Holdings
Institutions: 209
Institutional Holdings: 87.30M
% Owned: 95.68%
Shares Outstanding: 91.55M
TypeInstitutionsShares
Increased
48
10.96M
New
71
-2.76M
Decreased
35
7.78M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.25%
Pharmaceuticals & Medical Research
-1.11%
Key Executives
Chairman/Independent Director
Stephen Berenson
President/Chief Executive Officer/Director
Eric Shaff
Chief Financial Officer/Senior Vice President - Finance/Chief Accounting Officer
Marcus Chapman
Chief Human Resource Officer/Executive Vice President
Jayne Gansler
Executive Vice President/Chief Technology Officer
John Aunins
Executive Vice President/Chief Technology Officer
David Ege
Executive Vice President/Chief Scientific Officer
Matthew Henn
Executive Vice President/Secretary
Thomas DesRosier
Executive Vice President
Lisa von Moltke
Executive Vice President
Terri Young
Independent Director
Dennis Ausiello
Independent Director
Gregory Behar
Independent Director
Paul Biondi
Independent Director
Willard Dere
Independent Director
Kurt Graves
Independent Director
Richard Kender
Independent Director
Meryl Zausner
No Data
About MCRB
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.

Webull offers kinds of Seres Therapeutics Inc stock information, including NASDAQ:MCRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MCRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MCRB stock methods without spending real money on the virtual paper trading platform.